The Cell Imaging and Microscopy Shared Resource (CIM) provides cellular imaging technologies and services to enhance the programmatic research objectives of the Winship Cancer Institute (Winship). It is centrally located in Winship and houses state-of-the-art technologies including point scanning confocal, live cell confocal, spectral confocal imaging, epifluorescence microscopy, and image processing and analysis. CIM services have supported numerous Winship programmatic initiatives that include cancer cell biology, biomarker development, cancer nanotechnology, tumor diagnostics, drug delivery, and molecular pharmacology. These interactions have resulted in high Impact publications, team science grants, and inter- and intra-programmatic collaborations. Winship members comprise 88% of total CIM usage, with overall usage increasing from 1533 hours in calendar year 2008 to 4332 hours in 2010. CIM personnel provide consultation on experimental setup, execution, and analysis to ensure optimal image acquisition and data analysis. This includes comprehensive training sessions and dally user assistance to ensure that technologies are properly utilized. Alt user image data are archived nightly onto NAS enterprise level RAID protected servers to provide secure data backup. The CIM is a Winship shared resource, and Winship is responsible for oversight, operations, budget, compliance, user fee collection, and employee relations. The CIM Director makes all day-to-day decisions with input from CIM personnel, users, an internal advisory board, and executive oversight committee. The primary objectives of the CIM over the next two years are to expand small animal fluorescence imaging resources, implement a new assay development service, and continue to expand our IT infrastructure. These new technologies along with existing CIM services will enhance Winship's basic, translational, and clinical initiatives of Winship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-06
Application #
8634046
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$70,239
Indirect Cost
$25,214
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94
Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42
Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527
Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64
Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16
Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111
Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41
Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822

Showing the most recent 10 out of 210 publications